Share

cover art for How to fix the UK pensions problem & a swathe of takeover bids: The Companies and Markets Show

Investors' Chronicle

How to fix the UK pensions problem & a swathe of takeover bids: The Companies and Markets Show

We start with Smiths Group’s (SMIN) results. The engineering giant’s figures missed expectations, but could new acquisitions and an updated cost-saving plan bring things back? Michael Fahy reports. 


Our Big Read this week is on pensions. We all know what they are, but there’s much more that could be done for savers and perhaps for the wider economy – Alex Hamer, author of the cover feature, gives a rundown of the reforms mentioned in the piece that could boost pots, and breathe new life into the stock market.


We wrap up by touching on bid takeover activity. From Rightmove (RMV) to Advanced Medical Solutions (AMS), Jennifer Johnson unpacks everything investors need to know from the past week.


Timestamps

01:18  Smiths Group 

09:08  Pensions

23:59 Small caps

28:55 Takeovers

More episodes

View all episodes

  • Vietnam and India will benefit from China’s fall: Carson Block of Muddy Waters Resrearch

    36:21|
    Founded in 2010 by Carson Block, Muddy Waters Research is best known for its short-selling, predominantly in the mid-cap space. In this episode of IC Interviews, Block joins Dave Baxter to discuss what it would take for him to bet against the Magnificent Seven, the UK activist investing landscape, opportunities in Vietnam and India, and why China is uninvestable. This episode was recorded on 5 February. Timestamps 00:31 State of short selling9:04 What could change the market 16:30 Going against the Magnificent 718:16 Opportunities in UK sectors 21:28 Saba Capital23:18 Vietnam fund27:15 China30:48 India33:03 How short and long differClaim your first 12 weeks of Investors' Chronicle Print + Digital for just £12. You will get instant access to our website and app, plus the magazine delivered to your door every week. To start your trial, visit www.investorschronicle.co.uk/podcasttrial *After your 12-week trial you will pay just £62 every 13 weeks by direct debit. If you’re not entirely satisfied, you can cancel up to 5 business days before your renewal date and only pay the £12 already debited. This offer is for UK subscribers only.
  • Renishaw, Filtronic & British American Tobacco: The Companies and Markets Show

    36:24|
    Christoper Akers kicks off the podcast with engineer Renishaw’s (RSW) results. From supply chain issues to long-standing murmurs of a sale, find out why investors were disappointed.Valeria Martinez then unpacks designer and manufacturer Filtronic (FTC), whose results were warmly received by the market. Listen to find out how the firm landed contracts with SpaceX, which has been a leading factor in its 300 per cent share price increase over the past year, and how it is expanding to grow its customer base. Last up, we cover British American Tobacco (BAT). Its latest results were not as strong as hoped, thanks to a struggling tobacco alternatives market and strong competition from Philip Morris (PM). Mark Robinson explains all investors need to know.This episode was recorded on 13 February. Timestamps1:30 Renishaw9:24 Filtronic 25:06 British American Tobacco Claim your first 12 weeks of Investors' Chronicle Print + Digital for just £12. You will get instant access to our website and app, plus the magazine delivered to your door every week. To start your trial, visit www.investorschronicle.co.uk/podcasttrial *After your 12-week trial you will pay just £62 every 13 weeks by direct debit. If you’re not entirely satisfied, you can cancel up to 5 business days before your renewal date and only pay the £12 already debited. This offer is for UK subscribers only.
  • Why finance should be taught in schools: Lee and the IC

    35:30|
    This month, Lord Lee and Alex are joined by Member of Youth Parliament, Cameron Holt. At just 16 years old, Cameron’s goal is to get the government to recognise it is failing children with financial literacy. He believes, that through incorporating it into the curriculum, children will increase their confidence in a post-education world, and be more wary of the dangers of online fraud and debt. In the episode, the trio unpack the issues facing children and young people. From ways schools, parents and grandparents can increase young people’s interest in finances, to a petition Cameron has started which he hopes will make financial education statutory in secondary schools across the UK.The podcast rounds up with an update from Lord Lee’s portfolio, including news on holdings Town Centre Securities (TOWN), Concurrent Technologies (CNC) and PZ Cussons (PZC), plus his take on how Donald Trump will affect the UK. Click here to sign Cameron’s petition to make financial lessons statutory in schools. If you have any questions you want to pose to Lord Lee and Alex, write to alex.newman@ft.comRead Cameron’s article for the Investors’ Chronicle hereTimestamps1:16 Cameron Holt 5:04 What needs to change with financial education 6:03 Lord Lee’s experience of learning about finance 9:59 Cameron’s study12:55 NatWest shares14:24 Do schools offer financial advice on university 16:14 How to bridge the gap in financial literacy among children 21:35 Cameron’s petition 24:51 Updates on Lord Lee’s portfolio 27:45 Town Centre Securities29:42 Supermarket Income Reit30:41 Concurrent Technologies31:47 PZ CussonsClaim your first 12 weeks of Investors' Chronicle Print + Digital for just £12. You will get instant access to our website and app, plus the magazine delivered to your door every week. To start your trial, visit www.investorschronicle.co.uk/podcasttrial *After your 12-week trial you will pay just £62 every 13 weeks by direct debit. If you’re not entirely satisfied, you can cancel up to 5 business days before your renewal date and only pay the £12 already debited. This offer is for UK subscribers only.
  • Pharma results, Crest Nicholson & Compass Group: The Companies and Markets Show

    36:39|
    Julian Hofmann opens today’s podcast by unpacking results from AstraZeneca (AZN) and GSK (GSK). AstraZeneca had a particularly strong quarter despite China’s investigation into the importation of cancer drug, Imjudo. GSK’s dividends were up, positive news for income investors, but its vaccine rates have slowed as they are more exposed to the US administration. Julian shares all investors need to know.It’s then on to housebuilder Crest Nicholson (CRST). There is growing concern around its £144mn loss, but Natasha Voase lays out whether the worry is justified.Lastly, catering company Compass Group (CPG) released a trading update which showed strong organic growth. Mark Robinson explores the structural drivers behind this, its M&A strategy and its prospects. Timestamps01:52 AstraZeneca15:49 Crest Nicholson27:41 Compass GroupClaim your first 12 weeks of Investors' Chronicle Print + Digital for just £12. You will get instant access to our website and app, plus the magazine delivered to your door every week. To start your trial, visit www.investorschronicle.co.uk/podcasttrial *After your 12-week trial you will pay just £62 every 13 weeks by direct debit. If you’re not entirely satisfied, you can cancel up to 5 business days before your renewal date and only pay the £12 already debited. This offer is for UK subscribers only.
  • Some European stocks will be protected from Trump: Sam Gleave of Liontrust European Dynamic

    26:34|
    In the latest episode of the IC Interviews, Dave Baxter sits down with Sam Gleave of Liontrust’s European Dynamic. The fund seeks out companies lowly valued by investors, but that could generate more cash than they need to sustain strong growth. In the episode, Dave and Sam discuss why the fund is still bullish on European markets, the outlook for banks on the continent, plus how the fund views Hermes (RMS), Novo Nordisk (NOVO.B) and ASML (ASML). The pair also unpack what impact Trump’s swathe of tariffs will have on the fund and European companies at wide. This episode was recorded on 24 January.Timestamps 0:33 2025 outlook 2:57 China plays4:15 Industrials4:52 Luxury7:07 M&A 8:48 Banks12:49 Novo Nordisk (NOVO.B)16:47 ASML (ASML) 18:19 Trump, tariffs and the fund20:13 Publicis (PUB)22:02 Sectors Liontrust are wary of23:24 Is the opportunity set growingClaim your first 12 weeks of Investors' Chronicle Print + Digital for just £12. You will get instant access to our website and app, plus the magazine delivered to your door every week. To start your trial, visit www.investorschronicle.co.uk/podcasttrial *After your 12-week trial you will pay just £62 every 13 weeks by direct debit. If you’re not entirely satisfied, you can cancel up to 5 business days before your renewal date and only pay the £12 already debited. This offer is for UK subscribers only.
  • DeepSeek, Tesco & AJ Bell: The Companies and Markets Show

    38:21|
    Our panel kick off the podcast with a rundown of the latest news from the AI world. Chinese-owned DeepSeek’s smarter and more sustainable design helped knock half a billion dollars from Nvidia’s (NVIDIA) market cap. The panel discuss what comes next for AI stocks and return-hungry investors. It’s then on to Michael Fahy to chat about this week’s main feature on Tesco (TSCO). Michael explores how the supermarket's position has changed over the past few years, the mistakes it has made along the way and what comes next. Last up Val Cipriani and Julian Hoffman discuss AJ Bell’s (AJB) recent trading update. Listen to find out how the Budget has impacted the investing platform and how investors should consider the stock moving forward.Timestamps 1:17 DeepSeek13:01 Tesco28:04 AJ BellClaim your first 12 weeks of Investors' Chronicle Print + Digital for just £12. You will get instant access to our website and app, plus the magazine delivered to your door every week. To start your trial, visit www.investorschronicle.co.uk/podcasttrial *After your 12-week trial you will pay just £62 every 13 weeks by direct debit. If you’re not entirely satisfied, you can cancel up to 5 business days before your renewal date and only pay the £12 already debited. This offer is for UK subscribers only.
  • Predicting the market, US banks & biotech: The Companies and Markets Show

    36:02|
    On the week Donald Trump retook the position of US president, a handful of banking stocks released strong results. Jemma Slingo joins host Dan Jones to explore what investors need to know about Trump’s potential impact, the differences between UK and US banks, and a broader outlook for the year. It’s then onto this week’s cover feature on creating five-year outlooks for markets. Alex Newman runs through his thinking behind the piece, the challenges that arise when predicting market moves, and his predictions for gold.Last up, Julian Hoffman talks weight-loss drugs. He and Dan discuss what investors can expect in the year ahead, why Novo Nordisk’s results were disappointing, and more. Timestamps 1:11 US banks12:22 A five-year outlook24:58 BiotechClaim your first 12 weeks of Investors' Chronicle Print + Digital for just £12. You will get instant access to our website and app, plus the magazine delivered to your door every week. To start your trial, visit www.investorschronicle.co.uk/podcasttrial *After your 12-week trial you will pay just £62 every 13 weeks by direct debit. If you’re not entirely satisfied, you can cancel up to 5 business days before your renewal date and only pay the £12 already debited. This offer is for UK subscribers only.
  • ‘Trusts need to do better’: Boaz Weinstein of Saba Capital

    30:28|
    Dave Baxter and Dan Jones sit down with the founder of Saba Capital, Boaz Weinstein. Last month, Saba sent the investment trust space into disarray by announcing it wanted to unseat board members at seven underperforming trusts, and merge them or offer shareholders a way out.In the episode, Dave and Dan grill Boaz on how Saba’s plans would work, what happens if it doesn’t win the votes, his belief that investors will benefit and more.The deadlines for shareholders to vote on Saba’s proposals vary, but in many cases, they are due before the end of January: check with your platform for details.How to vote in Saba's big investment trust battleTimestamps 1:45 Are we too preoccupied with discounts?5:04 Critiques of Saba6:53 The plan when the results are in10:05 Professional investors’ view 12:21 If they don’t win the votes15:01 Cash exits for trusts 16:53 Trusts’ unlisted holdings eg. SpaceX19:57 The strategy for a new super-entity23:31 Where Saba’s attention will turn next25:55 If they win the vote, will they mimic US processes?28:10 Can Saba keep discounts in check?Claim your first 12 weeks of Investors' Chronicle Print + Digital for just £12. You will get instant access to our website and app, plus the magazine delivered to your door every week. To start your trial, visit www.investorschronicle.co.uk/podcasttrial *After your 12-week trial you will pay just £62 every 13 weeks by direct debit. If you’re not entirely satisfied, you can cancel up to 5 business days before your renewal date and only pay the £12 already debited. This offer is for UK subscribers only.
  • Small-cap income stocks & Games Workshop: The Companies and Markets Show

    34:38|
    This week’s episode starts off with a discussion of Games Workshop’s (GAW) results which showed strong core revenues. Valeria Martinez looks at how the business is performing geographically, the catalysts of its growth, its forecasts and more. Julian Hofmann then gives listeners an insight into our latest cover feature on dividend minnows. He shares the background of his research on the history of dividends in the FTSE 100 and highlights what investors should be wary of when it comes to large-cap dividends. He also touches on some examples from the piece such as brickmaker, Brickabilty (BRCK). Last up is the pig and cattle genetics company Genus (GNS). Shares were up 20 per cent in just one day earlier in the week, a change of tune from its performance in previous years. Julian touches on the backdrop for the company’s performance and why it’s hard to price. Timestamps1:09 Games Workshop 17:00 Income minnows 25:34 GenusClaim your first 12 weeks of Investors' Chronicle Print + Digital for just £12. You will get instant access to our website and app, plus the magazine delivered to your door every week. To start your trial, visit www.investorschronicle.co.uk/podcasttrial *After your 12-week trial you will pay just £62 every 13 weeks by direct debit. If you’re not entirely satisfied, you can cancel up to 5 business days before your renewal date and only pay the £12 already debited. This offer is for UK subscribers only.